Prolymphocytic leukemias

Seminars in Oncology
Biju KrishnanClaire Dearden

Abstract

T and B subtypes of prolymphocytic leukemias (PLLs) are rare, highly aggressive lymphoid malignancies with characteristic morphologic, immunophenotypical, cytogenetic, and molecular features. Recent studies have highlighted the role of specific oncogenes such as TCL1, MTCP-1, and ATM in the case of T-cell and p53 mutations in the case of B-cell PLLs. Despite the advances in the understanding of the biology of these conditions, prognosis for these patients remains poor with short survival and no curative treatment. The advent of monoclonal antibody therapy has improved treatment options for this group. In particular, the use of Campath-1H, in T-PLL has more than doubled median survival. The role of allogeneic transplant with nonmyeloablative conditioning needs to be explored further.

References

Sep 1, 1986·British Journal of Haematology·E MatutesD Catovsky
May 1, 1974·British Journal of Haematology·D A GaltonG J Goldenberg
Aug 1, 1981·British Journal of Haematology·D G OscierD A Galton
Jul 1, 1982·British Journal of Haematology·P J PriceJ B Stokes
Feb 1, 1996·Journal of Clinical Pathology·E MatutesD Catovsky
Jul 12, 1996·Cell·C BarlowA Wynshaw-Boris
Jan 31, 1998·British Journal of Haematology·D LensD Catovsky
Mar 6, 1998·Oncogene·M A YuilleD Catovsky
May 15, 1998·Bone Marrow Transplantation·R H CollinsJ W Fay
May 22, 1998·Cancer Genetics and Cytogenetics·F SoléJ Sans-Sabrafen
Jan 6, 2000·Journal of the National Cancer Institute·J M LeglerM S Linet
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J KeatingP Hérait

❮ Previous
Next ❯

Citations

Mar 28, 2009·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Tadeusz RobakPawel Robak
Mar 7, 2008·Expert Opinion on Emerging Drugs·Tadeusz Robak
Jul 7, 2009·Hematology/oncology Clinics of North America·Dragan Jevremovic, David S Viswanatha
Dec 17, 2008·Clinical Lymphoma & Myeloma·Claudiu V Cotta, Eric D Hsi
Jan 2, 2007·Cancer Letters·Amit W Panwalkar, James O Armitage
Aug 29, 2009·American Journal of Hematology·Paolo GallipoliMike Leach
Oct 26, 2006·British Journal of Haematology·Fatih M UckunSanjive Qazi
Jun 4, 2011·Cytometry. Part B, Clinical Cytometry·Samer Z Al-Quran
Feb 27, 2008·International Reviews of Immunology·Fatih M Uckun
Dec 2, 2010·Blood·Emilio Iannitto, Claudio Tripodo
Feb 15, 2017·American Journal of Hematology·Zhihong HuXinyan Lu
Jun 26, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bu YinCraig H Bassing
Jun 17, 2020·International Journal of Laboratory Hematology·Camille DebordMarie C Béné

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Related Papers

Current Treatment Options in Oncology
Ahmed AbsiMatt Kalaycio
Clinical Lymphoma & Myeloma
Farhad RavandiMichael J Keating
© 2022 Meta ULC. All rights reserved